These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21646396)

  • 1. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.
    Rusert P; Krarup A; Magnus C; Brandenberg OF; Weber J; Ehlert AK; Regoes RR; Günthard HF; Trkola A
    J Exp Med; 2011 Jul; 208(7):1419-33. PubMed ID: 21646396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
    Cale EM; Gorman J; Radakovich NA; Crooks ET; Osawa K; Tong T; Li J; Nagarajan R; Ozorowski G; Ambrozak DR; Asokan M; Bailer RT; Bennici AK; Chen X; Doria-Rose NA; Druz A; Feng Y; Joyce MG; Louder MK; O'Dell S; Oliver C; Pancera M; Connors M; Hope TJ; Kepler TB; Wyatt RT; Ward AB; Georgiev IS; Kwong PD; Mascola JR; Binley JM
    Immunity; 2017 May; 46(5):777-791.e10. PubMed ID: 28514685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
    Guzzo C; Zhang P; Liu Q; Kwon AL; Uddin F; Wells AI; Schmeisser H; Cimbro R; Huang J; Doria-Rose N; Schmidt SD; Dolan MA; Connors M; Mascola JR; Lusso P
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.
    Pan R; Gorny MK; Zolla-Pazner S; Kong XP
    J Virol; 2015 Aug; 89(15):8003-10. PubMed ID: 26018158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant: evidence for two distinct conformations.
    Ebenbichler C; Westervelt P; Carrillo A; Henkel T; Johnson D; Ratner L
    AIDS; 1993 May; 7(5):639-46. PubMed ID: 7686374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.
    Powell RLR; Totrov M; Itri V; Liu X; Fox A; Zolla-Pazner S
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
    Huisman JG; Carotenuto A; Labrijn AF; Papavoine CH; Laman JD; Schellekens MM; Koppelman MH; Hilbers CW
    Biochemistry; 2000 Sep; 39(35):10866-76. PubMed ID: 10978173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.